<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00653614</url>
  </required_header>
  <id_info>
    <org_study_id>91765</org_study_id>
    <secondary_id>2007-005258-22</secondary_id>
    <secondary_id>311926</secondary_id>
    <nct_id>NCT00653614</nct_id>
  </id_info>
  <brief_title>Cycle Control and Safety of E2-DRSP</brief_title>
  <official_title>A Multi-center, Double-blind, Randomized, Parallel-group Study to Evaluate Cycle Control and Safety of 6 Different Regimens of an Oral Contraceptive Containing Estradiol and Drospirenone in Healthy Female Volunteers Aged Between 18 and 35 Years Over 7 Cycles</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will be performed as a multi-center, randomized, double-blind, parallel-group trial
      in fertile women aged between 18 and 35 years inclusive. A total of 600 volunteers will be
      randomized into one of the six treatment groups. The study will be performed only in Germany.
      The investigational drug is an oral contraceptive. It contains the estrogen estradiol (E2)
      and the progestogen drospirenone (DRSP). As the contraceptive efficacy has not yet been
      proven for these new regimens, even a protection against unwanted pregnancies cannot be
      assured. The treatments will be applied daily for 7 cycles of 28 days each without pill-free
      interval, i.e., for 196 consecutive days. Treatment will be initiated after a screening
      period of approximately 1 to 2 weeks, the latter focused on confirmation of the baseline
      safety status. Tablet intake will start on the first day of the first menstrual/withdrawal
      bleeding after Visit 2, regardless of whether the volunteer is a first user (starter) or
      switching from another COC. In the following cycles, tablet intake is not to be triggered by
      any bleeding events. The primary objective of this study is to evaluate and compare the cycle
      control and bleeding patterns of six different treatment regimens with E2/DRSP during
      administration for 7 treatment cycles. Volunteers will be provided with a diary to document
      the intake of study medication, any bleeding events, and days without bleeding, pregnancy
      test results. Safety will be also assessed. During the whole study period, 4 visits are
      planned. At Screening and Final examination, a thorough physical examination and a
      gynecological examination (including breast palpation and cervical smear ) will be performed.
      Blood samples will be taken for safety laboratory parameters.Additional examinations can be
      performed any time, if this becomes necessary for medical reasons. At Visit 3 or in case of
      premature discontinuation of study the investigator will discuss options for follow-up
      contraception with the volunteer. The volunteer can start the intake of a post-treatment OC
      on the day after the last tablet intake of study medication, after a negative urine ß-HCG
      test (home pregnancy test) result.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of intracyclic bleeding episodes during cycles 2 to 7</measure>
    <time_frame>168 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of intracyclic bleeding days (including spotting) in Cycles 2 to 7</measure>
    <time_frame>168 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of withdrawal bleeding episodes in Cycles 1 to 6</measure>
    <time_frame>168 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding pattern</measure>
    <time_frame>Approximately 7 months</time_frame>
    <description>Bleeding pattern was determined by: - Number of bleeding/spotting days - Number of bleeding days (excluding spotting) - Number of spotting-only days - Number, mean length, maximum length, and range of length of bleeding/spotting episodes - Number, mean length, maximum length, and range of length of spotting-only episodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cycle control</measure>
    <time_frame>Approximately 7 months</time_frame>
    <description>Withdrawal bleeding - Number of volunteers with/without withdrawal bleeding; - Length, maximum intensity, and onset of withdrawal bleeding episodes Intracyclic bleeding (including/excluding spotting) - Number of volunteers with/without intracyclic bleeding; - Number, maximum length, maximum intensity (including spotting only) of intracyclic bleeding episodes - Number of intracyclic bleeding days - Number of volunteers with at least one intracyclic bleeding (including/excluding spotting) episode in Cycles 2 - 6 and in Cycles 2 - 7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective assessment of treatment</measure>
    <time_frame>Day 196 - Day 210</time_frame>
    <description>The treatment satisfaction assessment was done through a questionaire. The investigator handed it over to the subject and the subject was asked to answer all questions by herself.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>Approximately 7 months</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">635</enrollment>
  <condition>Contraceptive, Oral, Hormonal</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>E2/DRSP (BAY 86-4891) dose 1 (SHT04984E) for 24 days and DRSP (ZK 30595) dose 1 (SHT04984F) for one day and placebo for three days in a 28 day cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>E2/DRSP (BAY 86-4891) dose 1 (SHT04984E) for 24 days and DRSP (ZK 30595) dose 1 (SHT04984F) for two days and placebo for two days in a 28 day cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>E2/DRSP (BAY 86-4891) dose 2 (80458739) for days 1-8, E2/DRSP (BAY 86-4891) dose 1 (SHT04984E) for days 9-16, E2/DRSP (BAY 86-4891) dose 3 (80458755) for days 17-24, and placebo for days 25-28 in a 28 day cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>E2/DRSP (BAY 86-4891) dose 2 (80458739) for days 1-8, E2/DRSP (BAY 86-4891) dose 1 (SHT04984E) for days 9-16, E2/DRSP (BAY 86-4891) dose 3 (80458755) for days 17-24, placebo for 3 days, and DRSP (ZK 30595) dose 1 (SHT04984F) for one day in a 28 day cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>E2/DRSP (BAY 86-4891) dose 2 (80458739) for days 1-8, E2/DRSP (BAY 86-4891) dose 4 (80458720) for days 9-16, E2/DRSP (BAY 86-4891) dose 5 (80458712) for days 17-24, and placebo for 4 days in a 28 day cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>E2/DRSP (BAY 86-4891) dose 2 (80458739) for days 1-8, E2/DRSP (BAY 86-4891) dose 4 (80458720) for days 9-16, E2/DRSP (BAY 86-4891)dose 5 (80458712) for days 17-24, placebo for 3 days, and DRSP (ZK 30595) dose 2 (80458690) for one day in a 28 day cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E2/DRSP (BAY 86-4891) dose 1 (SH T04984E)</intervention_name>
    <description>Single dose administration of E2 + DRSP as a tablet</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_label>Arm 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E2/DRSP (BAY 86-4891) dose 2 (80458739)</intervention_name>
    <description>Single dose administration of E2 + DRSP as a tablet</description>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_label>Arm 4</arm_group_label>
    <arm_group_label>Arm 5</arm_group_label>
    <arm_group_label>Arm 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E2/DRSP (BAY 86-4891) dose 3 (80458755)</intervention_name>
    <description>Single dose administration of E2 + DRSP as a tablet</description>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_label>Arm 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E2/DRSP (BAY 86-4891) dose 4 (80458720)</intervention_name>
    <description>Single dose administration of E2 + DRSP as a tablet</description>
    <arm_group_label>Arm 4</arm_group_label>
    <arm_group_label>Arm 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E2/DRSP (BAY 86-4891) dose 5 (80458712)</intervention_name>
    <description>Single dose administration of E2 + DRSP as a tablet</description>
    <arm_group_label>Arm 5</arm_group_label>
    <arm_group_label>Arm 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DRSP (ZK 30595) dose 1 (SH T04984F)</intervention_name>
    <description>Single dose administration of DRSP as a tablet</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DRSP (ZK 30595) dose 2 (80458690)</intervention_name>
    <description>Single dose administration of DRSP as a tablet</description>
    <arm_group_label>Arm 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo administration in each arm</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_label>Arm 4</arm_group_label>
    <arm_group_label>Arm 5</arm_group_label>
    <arm_group_label>Arm 6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy female volunteers

          -  Age: 18 - 35 years (inclusive), smokers must not be older than 30 years at inclusion

          -  History of regular cyclic menstrual periods (with a cycle length between 25 and 35
             days)

          -  Willingness to use barrier methods of contraception (condoms with spermicide,
             diaphragms with spermicide, spermicidal vaginal suppositories) or abstinence during
             the trial

        Exclusion Criteria:

          -  Pregnancy, lactation (less than three menstrual cycles before Visit 1 following
             delivery, abortion, or lactation) - Obesity (BMI &gt; 30.0 kg/m2)

          -  Abnormal, suspicious or unclear cervical smear (a cervical smear has to be taken at
             Visit 1 or a normal result has to be documented within the last 6 months before Visit
             1)

          -  Laboratory values outside inclusion range at Screening - Any disease that may worsen
             under hormonal treatment or might interfere with the conduct of the study or the
             interpretation of the results, as e.g.: - Cardiovascular -- presence or a history of
             venous or arterial thrombotic/thromboembolic events (e.g., deep venous thrombosis,
             pulmonary embolism, myocardial infarction) or of a cerebrovascular accident, including
             prodromi (e.g., transient ischemic attack, angina pectoris) and conditions which could
             increase the risk to suffer from any of the above mentioned disorders, e.g., a family
             history indicating a hereditary predisposition. -- uncontrolled arterial hypertension
             (repeated measurements of systolic blood pressure &gt; 140 mmHg and/or diastolic blood
             pressure &gt; 90 mmHg)

          -  Liver -- presence or history of liver tumor (benign or malignant) -- presence or
             history of severe hepatic disease as long as liver function values have not returned
             to normal -- jaundice and/or pruritus related to cholestasis -- history of cholestatic
             jaundice associated with pregnancy or previous COC use

          -  Metabolic diseases -- uncontrolled diabetes mellitus with vascular involvement severe
             dyslipoproteinemia

          -  Other diseases: any known or suspected malignant or premalignant disease, uncontrolled
             thyroid disorder, chronic inflammatory bowel disease, severe renal insufficiency or
             acute renal failure, hemolytic uremic syndrome, sickle cell anemia, porphyria, history
             of hypertriglyceridemia-associated Pancreatitis, systemic lupus erythematodes,
             pemphigoid gestationis during a previous pregnancy, Sydenham chorea, herpes
             gestationis, otosclerosis-related hearing loss, history of migraine with focal
             neurologic symptoms, epilepsy, current or history of clinically significant
             depression, hereditary angioedema

          -  Additional sex steroids, other hormonal contraceptive methods (oral, transdermal)
             during treatment (blister in use at randomization should be finished); intra-uterine
             devices (IUD) with or without hormone release within 1 month prior to Visit 1,
             implants within 1 month prior Visit 1, depot progestins within 6 months prior to Visit
             1 - Surgical interventions scheduled in the study period
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Krumbach</city>
        <state>Bayern</state>
        <zip>86381</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nürnberg</city>
        <state>Bayern</state>
        <zip>90491</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dietzenbach</city>
        <state>Hessen</state>
        <zip>63128</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60322</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>65936</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fulda</city>
        <state>Hessen</state>
        <zip>36037</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mühlheim</city>
        <state>Hessen</state>
        <zip>63165</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Blankenburg</city>
        <state>Sachsen-Anhalt</state>
        <zip>38889</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Burg</city>
        <state>Sachsen-Anhalt</state>
        <zip>39288</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jessen</city>
        <state>Sachsen-Anhalt</state>
        <zip>06917</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Magdeburg</city>
        <state>Sachsen-Anhalt</state>
        <zip>39104</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Magdeburg</city>
        <state>Sachsen-Anhalt</state>
        <zip>39126</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dippoldiswalde</city>
        <state>Sachsen</state>
        <zip>01744</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01169</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04207</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04299</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wurzen</city>
        <state>Sachsen</state>
        <zip>04808</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gera</city>
        <state>Thüringen</state>
        <zip>07545</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>10247</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>12587</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>13086</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>13507</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <zip>21073</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <zip>22159</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <link>
    <url>http://www.bayerpharma.com/en/research-and-development/clinical-trials/trial-finder/index.php</url>
    <description>Click here to find results for studies related to Bayer Healthcare products.</description>
  </link>
  <link>
    <url>http://www.clinicaltrialsregister.eu/</url>
    <description>Click here to find information about studies related to Bayer Healthcare products conducted in Europe</description>
  </link>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 2, 2008</study_first_submitted>
  <study_first_submitted_qc>April 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2008</study_first_posted>
  <last_update_submitted>April 21, 2015</last_update_submitted>
  <last_update_submitted_qc>April 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Oral contraception</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Drospirenone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

